# Identification and Validation of a Macrophage Phagocytosis-Related Gene Signature for Prognostic Prediction in Colorectal Cancer (CRC)

## TL;DR

This study identifies a four-gene signature linked to macrophage phagocytosis in colorectal cancer, which helps predict patient outcomes and treatment responses.

## Contribution

A novel four-gene signature for CRC prognosis is developed and validated, linking phagocytosis-related genes to treatment response and survival.

## Key findings

- High-risk CRC patients show enhanced immunotherapy responsiveness compared to low-risk patients.
- qRT-PCR and IHC confirmed differential expression of SPHK1, FPR2, FCGR2B, and VSIG4 in cancer tissues.
- Single-cell RNA sequencing revealed gene expression changes during macrophage differentiation.

## Abstract

Emerging evidence highlights the critical role of phagocytosis-related genes in CRC progression, underscoring the need for novel phagocytosis-based prognostic models to predict clinical outcomes. In this study, a four-gene (SPHK1, VSIG4, FCGR2B and FPR2) signature associated with CRC prognosis was developed using single-sample gene set enrichment analysis (ssGSEA), least absolute shrinkage and selection operator (LASSO) regression, and univariate Cox analysis. Pathway enrichment analysis was conducted on the prognostic genes, along with evaluations of the tumor microenvironment and sensitivity to immunotherapy and chemotherapy across the high- and low-risk groups. Prognostic gene validation was performed via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) using CRC cDNA and tissue microarrays. High-risk patients showed enhanced responsiveness to immunotherapy, while chemotherapy sensitivity varied across risk subgroups. qRT-PCR results revealed upregulation of SPHK1 and FPR2 in cancer tissues, whereas FCGR2B and VSIG4 were downregulated. IHC assays confirmed increased SPHK1 and FPR2 expression in cancer samples. Single-cell RNA sequencing analysis demonstrated a decrease in SPHK1 and FCGR2B, while VSIG4 and FPR2 progressively increased during macrophage differentiation. These findings provide a potential framework for targeted therapy.